In clinical practice, PPARα agonists (fibrates) are used to treat hyperlipidemia, whereas PPARγ agonists (TZDs) are used to increase insulin sensitivity in muscle and adipose tissue [19], [35]. This evidence concerns the gene PPARA and hyperlipidemia.